Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Cancer
Michael Daneshvar
Prostate

Study Description

The purpose of this research study is to find out if Posluma (Flotufolastat F18), an investigational imaging drug, can accurately detect remaining prostate cancer in patients after receiving therapy to destroy the cancer (focal therapy).

Posluma is a radioactive diagnostic drug used in PMSA (prostate-specific membrane antigen) PET(postiron emission tomography) scans to help doctors locate prostate cancer in men. It is currently approved by the US Food and Drug Administration (FDA) in male patients with suspected metastisis (spreading to other parts of the body) or recurrence (return) of their cancer.

Because Posluma is not currently approved by the FDA in the detection of remaining cancer in patients after receiving focal therapy, it is considered investigational for the purposes of this study.

Eligibility

You can participate in this study if you

• Are 18 years old or older

• Have confirmed diagnosis of Prostate Cancer

You cannot participate in this study if you

• Have previously received treatment for your cancer, other than surgery to remove it.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.